WO2012122532A3 - Compositions and methods for treatment of hyperuricemia - Google Patents

Compositions and methods for treatment of hyperuricemia Download PDF

Info

Publication number
WO2012122532A3
WO2012122532A3 PCT/US2012/028616 US2012028616W WO2012122532A3 WO 2012122532 A3 WO2012122532 A3 WO 2012122532A3 US 2012028616 W US2012028616 W US 2012028616W WO 2012122532 A3 WO2012122532 A3 WO 2012122532A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
pharmaceutically acceptable
hydrate
acceptable salt
Prior art date
Application number
PCT/US2012/028616
Other languages
French (fr)
Other versions
WO2012122532A2 (en
Inventor
Alan HOLLISTER
William P. SHERIDAN
Shanta Bantia
Amy FLYNT
Jenna Elder
Anita WAUGH
Scott LYMAN
Original Assignee
Biocryst Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharmaceuticals, Inc. filed Critical Biocryst Pharmaceuticals, Inc.
Publication of WO2012122532A2 publication Critical patent/WO2012122532A2/en
Publication of WO2012122532A3 publication Critical patent/WO2012122532A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to methods and compositions for reduction of uric acid levels in subjects, and methods and compositions that are useful for treating, suppressing and/or preventing afflictions related to elevated uric acid levels in subjects. The methods comprise administering to the subject an effective amount of compound I, or a pharmaceutically acceptable salt or hydrate thereof, or a composition comprising compound I, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier. The compositions and/or methods may further comprise administering to the subject an effective amount of xanthine oxidase inhibitor such as allopurinol, or a pharmaceutically acceptable salt or hydrate thereof.
PCT/US2012/028616 2011-03-09 2012-03-09 Compositions and methods for treatment of hyperuricemia WO2012122532A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161450771P 2011-03-09 2011-03-09
US61/450,771 2011-03-09
US201161504161P 2011-07-01 2011-07-01
US61/504,161 2011-07-01

Publications (2)

Publication Number Publication Date
WO2012122532A2 WO2012122532A2 (en) 2012-09-13
WO2012122532A3 true WO2012122532A3 (en) 2014-04-24

Family

ID=46798848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/028616 WO2012122532A2 (en) 2011-03-09 2012-03-09 Compositions and methods for treatment of hyperuricemia

Country Status (1)

Country Link
WO (1) WO2012122532A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102600879B1 (en) * 2015-08-26 2023-11-09 가부시키가이샤 스타젠 Intracellular ATP enhancer
CN114341120A (en) * 2019-08-21 2022-04-12 国立大学法人东京大学 ABCC11 inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494912A (en) * 1991-06-26 1996-02-27 Merrell Pharmaceuticals Inc. 9-purinyl phosphonic acid derivitives for treating gout
US20090197825A1 (en) * 2007-11-27 2009-08-06 Ardea Biosciences, Inc. Novel compounds and compositions and methods of use
US20090239885A1 (en) * 2002-08-21 2009-09-24 Gary Brian Evans Inhibitors of nucleoside phoshorylases and nucleosidases
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494912A (en) * 1991-06-26 1996-02-27 Merrell Pharmaceuticals Inc. 9-purinyl phosphonic acid derivitives for treating gout
US20090239885A1 (en) * 2002-08-21 2009-09-24 Gary Brian Evans Inhibitors of nucleoside phoshorylases and nucleosidases
US20090197825A1 (en) * 2007-11-27 2009-08-06 Ardea Biosciences, Inc. Novel compounds and compositions and methods of use
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FITZ-PATRICK ET AL.: "Effects of a Purine Nucleoside Phosphorylase Inhibitor, BCX4208, on the Serum Uric Acid Concentrations in Patients with Gout.", APS- ACR POSTER SESSION A., 8 November 2010 (2010-11-08) *
GOMES ET AL.: "A Phase 2 Study of the Purine Nucleoside Phosphorylase (PNP) inhibitor R05092888 (BCX4208) in Patients with Moderate to Severe Chronic Plaque Psoriasis: Safety", TOLERABILITY AND LYMPHOCYTE EFFECTS - PRESENTED AT THE AMERICAN SOCIETY OF HEMATOLOGY 50TH ANNUAL MEETING & EXPOSITION (ASH), 6 December 2008 (2008-12-06), SAN FRANCISCO, CALIFORNIA *
LEWANDOWICZ ET AL.: "Energetic Mapping of Transition State Analogue Interactions with Human and Plasmodium falciparum Purine Nucleoside Phosphorylases.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 34, 26 August 2005 (2005-08-26), pages 30320 - 30328 *

Also Published As

Publication number Publication date
WO2012122532A2 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
WO2010021680A3 (en) Inhibitors of beta-secretase
WO2011133795A3 (en) Beta-carbolines as inhibitors of haspin and dyrk kinases
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2009108383A3 (en) Substituted xanthine derivatives
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MX2010007584A (en) Protein kinase inhibitors and use thereof.
WO2010017545A3 (en) Triazole compounds that modulate hsp90 activity
MX2013003938A (en) Methods and compositions for inhibition of polymerase.
WO2013163190A8 (en) Dna-pk inhibitors
EP2571876A4 (en) Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
WO2012017239A3 (en) 4-(1h-indol-3-yl) -pyrimidines as alk inhibitors
MX350761B (en) Isoindolinone inhibitors of phosphatidylinositol 3-kinase.
MX2012002705A (en) Substituted xanthine derivatives.
WO2010011772A3 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
WO2007089634A3 (en) Inhibitors of fatty acid synthase (fas)
WO2010135530A3 (en) Compounds, compositions and methods for modulating uric acid levels
WO2011159840A3 (en) Phenylthioacetate compounds, compositions and methods of use
SG195100A1 (en) Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
WO2012015986A3 (en) Substituted dioxopiperidinyl phthalimide derivatives
WO2012135697A3 (en) Novel rho kinase inhibitors and methods of use
MX2011011083A (en) Heterocyclic compounds as mek inhibitors.
WO2009114703A3 (en) Combination therapy for the treatment of cancer
MX2012009600A (en) Methods for stabilizing joint damage in subjects using xanthine oxidoreductase inhibitors.
IN2012DN01642A (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12754921

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12754921

Country of ref document: EP

Kind code of ref document: A2